| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000018161 |
| Receipt No. | R000021024 |
| Official scientific title of the study | Effect of fat metabolism by amino acids mixture during exercise on obesity men : a randomized, double-blind, placebo-controlled study |
| Date of disclosure of the study information | 2015/07/03 |
| Last modified on | 2016/07/04 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | Effect of fat metabolism by amino acids mixture during exercise on obesity men : a randomized, double-blind, placebo-controlled study | |
| Title of the study (Brief title) | Effect of fat metabolism by amino acids mixture during exercise on obesity men | |
| Region |
|
|
| Condition | ||
| Condition | No (Subjects whose BMI are 25 to 30) | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To examine the lipid metabolism effect by administration of amino acids mixture during exercise. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Blood glycerol level |
| Key secondary outcomes | |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Randomized |
| Randomization unit | Cluster |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Capsules containing 3 g of amino acids mixture, 1 per serving 1 trial | |
| Interventions/Control_2 | Capsules containing 3 g of dextrin, 1 per serving 1 trial | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male | |||
| Key inclusion criteria | <1>Subjects giving written informed consent
<2>Men 30 to 50 years age 1) Men whose BMI of 25 to 30 and/or visceral fat area less than 200 cm 2. 2) Men who has no regular exercise (30 minutes or more / time more than three times a week) |
|||
| Key exclusion criteria | <1>Sever systemic diseases
<2>Subjects who drink a lot of alcohol <3>Smoker <4>Subjects whose eating habits are extremely irregular. <5>Midnight and irregular shift worker <6>Constant use of oral medication or supplements affecting body fat and/or body <7>Subjects who donated blood within 6 months before starting of administration. <8>Phenylketonuria, and hyperphenylalaninemia <9>Subjects who are judged as unsuitable for the study by the investigator for other reason. |
|||
| Target sample size | 12 | |||
| Research contact person | |
| Name of lead principal investigator | Katsuhisa Sakano |
| Organization | CPCC Company Limited |
| Division name | Clinical Research Planning Department |
| Address | 4F Chushin Build. 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047 Japan |
| TEL | 03-5297-3112 |
| k.s@cpcc.co.jp | |
| Public contact | |
| Name of contact person | Makoto Ichinohe |
| Organization | CPCC Company Limited |
| Division name | Plan Sales Department |
| Address | 4F Chushin Build. 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047 Japan |
| TEL | 03-5297-3112 |
| Homepage URL | |
| m.i@cpcc.co.jp | |
| Sponsor | |
| Institute | CPCC Company Limited |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | Meiji Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000021024 |